The partial dopamine (DA) D2 agonists, including aripiprazole, brexpiprazole, and cariprazine, represent a mechanistically distinct class within the second-generation antipsychotics (SGAs). Rather than blocking the D2 receptor, they act as partial agonists, producing submaximal receptor activation that has opposite effects depending on the prevailing state of dopaminergic tone in a given circuit.
A partial agonist at the D2 receptor occupies the receptor and activates it to a degree determined by its intrinsic efficacy, a value less than 100% relative to the full agonist dopamine. In a circuit where DA is in excess, as in the mesolimbic pathway in acute psychosis, the partial agonist displaces dopamine from the receptor and the net effect is functional antagonism: the partial agonist activates the receptor less than endogenous DA would, thereby dampening mesolimbic hyperactivity and reducing positive symptoms.1 In a circuit where DA is deficient, as in the mesocortical pathway underlying negative symptoms and cognitive deficits, the partial agonist provides some residual receptor activation that full antagonists do not, offering partial support of a hypodopaminergic state rather than worsening it. This functional selectivity, sometimes described as dopamine system stabilization, is the theoretical basis for the claim that partial agonists are better positioned than full antagonists to address negative symptoms and cognitive dysfunction without worsening the mesocortical dopamine deficit.
The practical consequences of partial D2 agonism are clinically significant. Extrapyramidal side effects (EPS) from nigrostriatal D2 blockade are substantially reduced relative to both first-generation antipsychotics (FGAs) and many full-antagonist second-generation antipsychotics (SGAs), because the partial agonist stabilizes rather than depletes nigrostriatal DA tone. Prolactin elevation is minimal to absent with all three partial agonists in this class, because the partial agonist provides enough D2 activation at the pituitary to maintain partial inhibition of prolactin secretion despite receptor occupancy, unlike full antagonists which remove all inhibitory DA tone and maximally elevate prolactin.1 The absence of prolactin elevation is a meaningful clinical advantage in younger patients, women of reproductive age, and patients where long-term bone density is a concern.
Akathisia is the most prominent adverse effect shared across the partial agonist class, occurring at meaningfully higher rates than with quetiapine or clozapine and at rates comparable to or exceeding low-dose risperidone at some dose levels. The mechanism of partial agonist-induced akathisia is not fully established but may involve partial agonism at mesolimbic D3 receptors or serotonergic mechanisms rather than purely nigrostriatal D2 activity.1 Management of akathisia on partial agonists follows the same principles as for other antipsychotics: dose reduction where feasible, propranolol for the subjective restlessness component, and mirtazapine as a second-line option. Switching within the partial agonist class may improve akathisia in some patients, as the three agents differ in their partial agonist intrinsic efficacy and receptor selectivity profiles.
Aripiprazole was the first partial D2 agonist approved for clinical use (2002) and remains the most widely prescribed agent in this mechanistic class. Its receptor profile combines partial D2 agonism with partial serotonin 5-HT1A agonism and antagonism at 5-HT2A receptors, a combination that may contribute to its broad clinical utility across psychotic, mood, and anxiety-spectrum conditions.1 At D2 receptors, aripiprazole has high affinity with an intrinsic efficacy of approximately 25 to 30% relative to dopamine, placing it in the low-intrinsic-efficacy partial agonist range that produces robust functional antagonism in hyperdopaminergic mesolimbic circuits while providing meaningful D2 activation in hypodopaminergic circuits. Its affinity for H1, M1, and alpha-1 adrenergic receptors is low, which directly accounts for its favorable metabolic, sedation, and orthostatic profiles compared with clozapine, olanzapine, and quetiapine.
Aripiprazole's Food and Drug Administration (FDA)-approved indications span schizophrenia (acute and maintenance), bipolar I disorder mania (acute and maintenance), as adjunctive therapy in major depressive disorder (MDD), irritability associated with autistic disorder, and Tourette syndrome. Its use as an adjunct in MDD is notable because it is one of very few antipsychotics approved for this indication, where its 5-HT1A partial agonism may contribute antidepressant-like effects at doses below those required for full antipsychotic effect.2 Aripiprazole long-acting injectable (LAI) formulations include Abilify Maintena (monthly IM) and Aristada (Aripiprazole lauroxil, available in 4-week, 6-week, and 8-week dosing intervals), offering one of the most flexible injection-interval options among SGA LAIs. Aristada Initio, a companion single-dose injection of aripiprazole lauroxil 675 mg administered with a single oral aripiprazole 30 mg dose, enables same-day Aristada initiation without a 21-day oral supplementation period.
Aripiprazole has the most favorable metabolic profile among broadly used antipsychotics, with mean weight gain of approximately 0.7 to 1.0 kg at 10 weeks in clinical trials and minimal effect on fasting glucose, lipids, or insulin sensitivity.3 This metabolic neutrality reflects its low H1 and 5-HT2C receptor affinity. In clinical practice, aripiprazole is frequently added to regimens that include metabolically burdensome antipsychotics, particularly olanzapine or clozapine, where it may attenuate weight gain through mechanisms that include partial D2 agonism in hypothalamic circuits. Randomized trials have shown that switching from olanzapine to aripiprazole produces meaningful reductions in weight, fasting glucose, and triglycerides while maintaining antipsychotic efficacy in patients who are not among the subset requiring olanzapine's specific efficacy advantages.3
Aripiprazole is metabolized primarily by cytochrome P450 (CYP) 2D6 and CYP3A4, with dehydro-aripiprazole as the principal active metabolite contributing approximately 40% of the total pharmacological activity. The plasma half-life of aripiprazole is approximately 75 hours, and of dehydro-aripiprazole approximately 94 hours, making aripiprazole one of the longest-acting oral antipsychotics and supporting once-daily dosing with a long washout after discontinuation.4 CYP2D6 poor metabolizers achieve aripiprazole plasma levels approximately double those of extensive metabolizers, requiring dose reduction to 50% of the standard dose. Strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) and strong CYP3A4 inhibitors (itraconazole, ketoconazole, clarithromycin) each raise aripiprazole levels substantially and individually warrant dose reduction to 50%; when both are co-administered simultaneously, aripiprazole dose should be reduced to one quarter of the original dose. Conversely, strong CYP3A4 inducers (carbamazepine, rifampin) reduce aripiprazole levels by approximately 70%, requiring dose doubling when added to stable aripiprazole therapy.
Brexpiprazole is a partial D2 and D3 agonist with partial 5-HT1A agonism and antagonism at 5-HT2A and alpha-1 adrenergic receptors. It was designed with a lower D2 intrinsic efficacy than aripiprazole, approximately 20% relative to dopamine, with the goal of reducing akathisia rates while maintaining antipsychotic efficacy.1 Clinical trial data suggest that brexpiprazole does produce numerically lower akathisia rates than aripiprazole, though the difference is modest and patient-level predictors of which agent will be better tolerated remain unclear. Its metabolic profile is comparable to aripiprazole, with low H1 and minimal anticholinergic activity. FDA-approved indications include schizophrenia and as adjunctive treatment of MDD.9 Brexpiprazole's alpha-1 adrenergic antagonism is more pronounced than aripiprazole's, which produces greater orthostatic hypotension during initiation and requires gradual dose titration starting at 0.5 to 1 mg per day.
Brexpiprazole is metabolized by CYP2D6 and CYP3A4 and follows the same drug interaction principles as aripiprazole with respect to enzyme inhibitors and inducers. Its half-life of approximately 91 hours supports once-daily dosing and a prolonged washout period. The combination of near-aripiprazole metabolic neutrality with potentially lower akathisia burden positions brexpiprazole as a reasonable alternative in patients who found aripiprazole intolerable due to akathisia, though head-to-head trial data comparing the two agents directly on akathisia rates are limited.4
Cariprazine is a partial D2 and D3 agonist with preferential affinity for the D3 receptor subtype over D2, distinguishing it pharmacologically from both aripiprazole and brexpiprazole. Its D3 to D2 affinity ratio is approximately 10:1, making it the most D3-selective compound among approved antipsychotics.5 D3 receptors are concentrated in limbic structures, particularly the nucleus accumbens and other ventral striatal regions, with relatively limited dorsal striatal expression. This limbic predominance makes D3 partial agonism theoretically attractive for addressing motivational and reward deficits characteristic of the negative symptom domain of schizophrenia, specifically avolition and anhedonia, without the degree of dorsal striatal D2 blockade that drives EPS.
The clinical evidence for cariprazine's benefit in negative symptoms is the most robust of any currently approved antipsychotic. The pivotal trial by Nemeth et al. (2017) in Lancet randomized patients with schizophrenia who had predominant negative symptoms to cariprazine versus risperidone in a 26-week head-to-head comparison and demonstrated significantly greater improvement in negative symptom scales with cariprazine at all assessment points.5 This was a prospective, adequately powered trial specifically designed to test negative symptom efficacy rather than a post-hoc subgroup analysis, making it the highest-quality evidence currently available for any pharmacological intervention specifically targeting primary negative symptoms. Cariprazine is also approved for schizophrenia (acute and maintenance), bipolar I mania, and bipolar depression, the last representing a distinct indication supported by dedicated phase III trials showing superiority to placebo on depressive outcome measures in bipolar I patients.
The active metabolite of cariprazine, didesmethyl-cariprazine (DDCAR), has a half-life of 1 to 3 weeks and accumulates substantially during treatment, making cariprazine one of the longest-effective-duration antipsychotics after discontinuation. Steady state of DDCAR is not reached until 4 to 8 weeks of continuous dosing, and DDCAR persists for weeks after cariprazine is stopped, a pharmacokinetic property that has implications for switching and for managing adverse effects: if intolerable akathisia or other dose-related effects emerge, their resolution may be slower than expected because the active metabolite continues to accumulate and then wash out slowly.4 EPS rates, particularly akathisia, are meaningful with cariprazine at the higher approved doses (4.5 to 6 mg per day) and represent the most common reason for dose reduction or discontinuation in clinical trials.
Ziprasidone is a benzisothiazolyl piperazine with high affinity for D2, 5-HT2A, 5-HT1A, 5-HT1D, and norepinephrine reuptake, and low affinity for H1 and M1 receptors. Its multi-receptor profile includes meaningful 5-HT1A partial agonism and serotonin and norepinephrine reuptake inhibition, which may contribute antidepressant-like properties. Its metabolic profile is the most favorable of all approved full-antagonist antipsychotics: mean weight gain of approximately 0.5 kg at 10 weeks in clinical trials, with minimal glucose and lipid effects, attributable to its very low H1 and 5-HT2C affinity.3
Ziprasidone's primary clinical limitation is QTc interval prolongation. It produces mean QTc prolongation of approximately 10 milliseconds at standard doses, greater than most other SGAs though substantially less than thioridazine. This QTc effect places ziprasidone in a higher cardiac risk category and makes it contraindicated in patients with a history of QTc prolongation, congenital long QT syndrome, or those taking other QTc-prolonging agents. Baseline electrocardiogram (ECG) is recommended before initiating ziprasidone, and periodic monitoring should be considered particularly when electrolyte abnormalities or QTc-prolonging co-medications are present.6 In practice, the actual incidence of serious cardiac arrhythmias with ziprasidone at therapeutic doses is very low, and QTc prolongation has not translated into increased mortality in clinical trial populations; however, the prescribing information requirement for caution has meaningfully constrained clinical uptake.
Ziprasidone's pharmacokinetics carry an important food dependency: oral bioavailability approximately doubles when taken with a meal of at least 500 calories compared with fasting conditions. Patients instructed to take ziprasidone without food may achieve plasma levels insufficient for antipsychotic effect, effectively receiving a lower functional dose than prescribed. All patients on oral ziprasidone should be counseled explicitly to take it with food at every dose. Ziprasidone is metabolized primarily by aldehyde oxidase and secondarily by CYP3A4, making its drug interaction profile somewhat different from most antipsychotics; CYP3A4 inhibitors raise ziprasidone levels modestly, while aldehyde oxidase inhibitors are rarely encountered clinically.
Lurasidone is a benzisothiazol derivative with high affinity for D2, 5-HT2A, 5-HT7, and partial 5-HT1A agonism, and moderate affinity for alpha-2 adrenergic receptors. Its low H1 and M1 affinity produces a favorable sedation, weight gain, and anticholinergic profile. Its 5-HT7 antagonism is pharmacologically distinctive and may contribute to its antidepressant and pro-cognitive properties.8,10 Like ziprasidone, lurasidone has very low metabolic liability, with weight gain averaging approximately 0.7 kg at 6 weeks in clinical trials, and minimal glucose and lipid effects, placing it among the most metabolically neutral full-antagonist antipsychotics available.
Lurasidone has the most extensively developed evidence base for bipolar depression of any agent in this module. It is FDA-approved for bipolar depression (as monotherapy and as adjunctive therapy with lithium or valproate), supported by the PREVAIL 1 and PREVAIL 2 trials, which demonstrated superiority over placebo on depressive rating scales in bipolar I depression without a significant risk of mood switching to mania.7 The approval for bipolar depression, combined with its favorable metabolic profile, makes lurasidone a frequent first-line choice in bipolar patients where long-term weight and metabolic management is a priority. For negative symptoms in schizophrenia, lurasidone has shown benefits in clinical trials that are generally considered secondary to cariprazine's but superior to most other SGAs, possibly attributable to its 5-HT7 antagonism promoting prefrontal cortex (PFC) dopaminergic tone.
Lurasidone shares ziprasidone's food dependency: oral bioavailability increases approximately three-fold when taken with at least 350 calories, and consistent administration with food is required for reliable plasma levels. Lurasidone is metabolized primarily by CYP3A4, and this single-enzyme dependence creates clinically meaningful interactions: co-administration with strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) is contraindicated because it raises lurasidone levels to potentially toxic concentrations; co-administration with strong CYP3A4 inducers (carbamazepine, rifampin, St. John's Wort) is also contraindicated because it may render lurasidone subtherapeutic.4 Unlike many antipsychotics, lurasidone does not prolong the QTc interval to a clinically meaningful degree, which represents an advantage when QTc management is a concern.
Asenapine is a tetracyclic antipsychotic with high affinity for D2, D3, D4, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, 5-HT7, alpha-1, alpha-2, and H1 receptors, one of the broadest receptor binding profiles among approved antipsychotics outside of clozapine. Its 5-HT2C antagonism is substantial, which contributes to meaningful weight gain (approximately 1.1 kg at 6 weeks) that is greater than ziprasidone or lurasidone but substantially less than olanzapine or clozapine.3 Its receptor profile, particularly the combination of 5-HT2A, 5-HT6, and 5-HT7 antagonism alongside D2 blockade, has generated interest in potential pro-cognitive effects, though clinical trial evidence for cognitive improvement beyond what is attributable to symptom reduction has been inconsistent. FDA-approved indications include schizophrenia (acute and maintenance) and bipolar I mania (acute, as monotherapy and as adjunctive therapy).
Asenapine's pharmacokinetics are distinctive and clinically important. It is available only as a sublingual formulation because its oral bioavailability is essentially zero when swallowed: extensive first-pass hepatic metabolism renders the molecule pharmacologically inactive via the gastrointestinal route, but sublingual absorption through the buccal mucosa yields approximately 35% bioavailability. Patients must be instructed to place the tablet under the tongue and allow it to dissolve completely without swallowing, and should not eat or drink for 10 minutes after administration to avoid washing the drug from the absorptive mucosa before adequate uptake occurs. Failure to follow these instructions consistently results in therapeutic failure that may be misattributed to treatment resistance. A transdermal patch formulation of asenapine (Secuado) is also approved for schizophrenia, providing an option for patients with compliance difficulties related to the sublingual requirement or for those with dysphagia.1
Asenapine is metabolized by CYP1A2 and direct glucuronidation. Fluvoxamine, a potent CYP1A2 inhibitor, raises asenapine plasma levels substantially. Smoking induces CYP1A2 and reduces asenapine levels, following the same pharmacokinetic smoking interaction pattern described for clozapine and olanzapine. A reversible oral numbness or hypoesthesia of the tongue and mouth occurs in a minority of patients shortly after sublingual dosing; it is benign and transient but should be anticipated in patient counseling to prevent premature discontinuation attributable to this effect.
Iloperidone is a piperidinyl-benzisoxazole with high affinity for D2, D3, 5-HT2A, and alpha-1 adrenergic receptors, and lower affinity for H1. Its alpha-1 blockade is among the most pronounced of any SGA, producing orthostatic hypotension that is sufficiently severe to require mandatory slow titration: the approved initiation protocol starts at 1 mg twice daily and increases by 2 mg increments per day over 7 days to reach a target dose. Failure to follow this titration schedule is associated with symptomatic orthostatic hypotension, syncope, and falls. Iloperidone produces modest QTc prolongation comparable to ziprasidone and requires baseline ECG assessment. Its metabolic profile is intermediate, with moderate weight gain and modest glucose effects. FDA-approved indication is schizophrenia only.1
Iloperidone's CYP2D6 and CYP3A4 metabolism makes it susceptible to the same inhibitor and inducer interactions as aripiprazole and risperidone. CYP2D6 poor metabolizers require dose reduction because they accumulate both the parent drug and the active P88 and P95 metabolites. Strong CYP2D6 or CYP3A4 inhibitors warrant dose reduction by 50%. Iloperidone occupies a relatively narrow clinical niche: its orthostatic hypotension burden and QTc considerations limit its broad use, and its efficacy profile is not clearly superior to other SGAs in any specific indication. It may be considered in patients who have failed or are intolerant of other agents where its specific receptor profile offers a rationale, or in patients who require very gradual titration due to cardiovascular sensitivity.
The newer SGAs in this module span a wide range of pharmacokinetic profiles, from aripiprazole's 75-hour half-life to ziprasidone's 7-hour half-life, and from aripiprazole's relative food independence to ziprasidone's and lurasidone's requirement for co-administration with food. These differences directly determine dosing frequency, ease of adherence, and the clinical consequences of missed doses.
Aripiprazole is metabolized by CYP2D6 and CYP3A4, with an oral half-life of approximately 75 hours for the parent drug and 94 hours for its active metabolite dehydro-aripiprazole; bioavailability is approximately 87% and is not significantly food-dependent. Brexpiprazole follows a similar CYP2D6 and CYP3A4 metabolic pattern with a half-life of approximately 91 hours. Cariprazine is also CYP3A4-dependent, with the parent drug half-life of 2 to 4 days and its major active metabolite DDCAR accumulating over weeks; full metabolic steady state of the active metabolite requires 4 to 8 weeks. Ziprasidone is metabolized primarily by aldehyde oxidase and secondarily by CYP3A4, with a half-life of approximately 7 hours requiring twice-daily dosing and food co-administration for adequate bioavailability. Lurasidone is CYP3A4-dependent with a half-life of 18 hours supporting once-daily dosing, but bioavailability requires food co-administration of at least 350 calories. Asenapine is metabolized by CYP1A2 and glucuronidation, with a half-life of approximately 24 hours; sublingual absorption provides approximately 35% bioavailability compared with essentially zero for swallowed tablets. Iloperidone is metabolized by CYP2D6 and CYP3A4, with a half-life of 18 hours in extensive metabolizers and longer in poor metabolizers.4
Aripiprazole's dual CYP2D6 and CYP3A4 metabolism creates additive interaction risks when both pathways are inhibited simultaneously. Fluoxetine and paroxetine (CYP2D6 inhibitors) alone: reduce aripiprazole dose by 50%. Ketoconazole or itraconazole (CYP3A4 inhibitors) alone: reduce dose by 50%. Both a CYP2D6 and a CYP3A4 inhibitor co-administered: reduce aripiprazole dose to 25% of original. Carbamazepine (CYP3A4 inducer): double aripiprazole dose. The same dose adjustment principles apply to brexpiprazole, which shares the same metabolic pathway. Cariprazine's CYP3A4 dependence means that strong CYP3A4 inhibitors raise cariprazine and DDCAR levels substantially; the prescribing information recommends halving cariprazine dose when a strong CYP3A4 inhibitor is added. Strong CYP3A4 inducers render cariprazine potentially subtherapeutic and their combination should be avoided or managed with careful dose adjustment and plasma level monitoring.4
Ziprasidone's aldehyde oxidase metabolism makes it relatively insensitive to most CYP inhibitors and inducers, though its CYP3A4 component means that strong CYP3A4 inhibitors can modestly raise ziprasidone levels. The primary drug interaction concern for ziprasidone is pharmacodynamic: additive QTc prolongation with other QTc-active drugs, including fluoroquinolone antibiotics, azole antifungals, some macrolides, antiarrhythmics (amiodarone, sotalol, quinidine), and methadone. These combinations require careful cardiac risk-benefit assessment and ECG monitoring. Lurasidone's exclusive CYP3A4 dependence makes strong CYP3A4 inhibitors and inducers absolute contraindications, not merely interactions requiring dose adjustment, because the magnitude of level change at either extreme is too large to reliably manage with dose modification.4 Asenapine's CYP1A2 dependence creates the smoking and fluvoxamine interactions described in Section 5. Iloperidone's combined CYP2D6 and CYP3A4 metabolism produces additive interaction risk when both are inhibited, analogous to aripiprazole, with a 50% dose reduction recommended for strong inhibitors of either pathway.
Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th ed. Cambridge: Cambridge University Press; 2013:129–237.
Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843–853.
doi:10.4088/jcp.v68n0604Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686–1696.
doi:10.1176/ajp.156.11.1686Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100(1):4–22.
doi:10.1111/j.1742-7843.2007.00017.xNemeth G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103–1113.
doi:10.1016/S0140-6736(17)30060-0Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001;158(11):1774–1782.
doi:10.1176/appi.ajp.158.11.1774Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160–168.
doi:10.1176/appi.ajp.2013.13070984Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011;65(2):189–210.
doi:10.1111/j.1742-1241.2010.02587.xKane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164(1–3):127–135.
doi:10.1016/j.schres.2015.01.038Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol. 2011;11(1):59–67.
doi:10.1016/j.coph.2011.02.007